What You Should Know About Gilead's Sovaldi And Johnson & Johnson's Olysio
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 24, 5:30PM CDT
Over the past five years, few drugs have been as highly anticipated as Gilead's Sovaldi, a new-generation oral treatment for hepatitis C infection. Sovaldi won FDA approval in December, and despite only being available for a few weeks, Sovaldi...
Final Glance: Pharmaceuticals companies
AP - Thu Apr 24, 5:04PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Alexion Posts Strong Earnings in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 4:00PM CDT
Alexion (ALXN) handsomely beat the Zacks Consensus Estimate in the first quarter.
Midday Glance: Pharmaceuticals companies
AP - Thu Apr 24, 12:27PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Bristol-Myers Squibb Ranks First on 2014 Best Corporate Citizens List
Business Wire - Thu Apr 24, 12:01PM CDT
Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has been ranked No. 1 on Corporate Responsibility magazine's 2014 list of the 100 Best Corporate Citizens, a leading benchmark for socially responsible investors and other stakeholders.
The Medicines Co.'s Q1 Earnings Surpass Expectations - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 10:40AM CDT
The Medicines Co. (MDCO) also announced an acquisition agreement which reflects its efforts to diversify its portfolio and reduce its dependence on Angiomax.
Early Glance: Pharmaceuticals companies
AP - Thu Apr 24, 9:33AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Is This Struggling Drugmaker Worth $100 Billion?
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 24, 8:30AM CDT
The pharmaceutical world got a shock this week from reports that Pfizer had engaged in informal talks with Big Pharma rival AstraZeneca about a possible $100 billion acquisition. AstraZeneca reportedly expressed no interest in the...
The Zacks Analyst Blog Highlights
PR Newswire - Thu Apr 24, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Pandora Media, Inc. (NYSE
AstraZeneca's Q1 Profit Falls 11% Despite Strong Diabetes Drug Growth
Sean Williams, The Motley Fool - Motley Fool - Thu Apr 24, 7:36AM CDT
Just days after rumors swirled about a possible takeover offer, global pharmaceutical giant AstraZeneca reported its first-quarter results very early this morning, delivering modest top-line growth but seeing its profits shrink notably. For...
Allied Minds Names Peter Dolan and Jeff Rohr to Board of Directors
Business Wire - Thu Apr 24, 7:03AM CDT
Allied Minds, a dedicated technology commercialization firm that develops businesses and products based on innovative technologies developed at US universities and federal research institutions, today announced the appointment of Peter Dolan and Jeff Rohr as new members of its Board of Directors, effectively immediately.
Quarterly Results, FDA Approvals, Intellectual Property Appeals, New Drug Applications, and Initiated Clinical Trials - Analyst Notes on Johnson & Johnson, Merck, Teva, Bristol-Myers Squibb and AbbVie
PR Newswire - Thu Apr 24, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Bristol-Myers Squibb Company (NYSE: BMY) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1516-100free.
Will These 3 Dividend Stocks Impress Investors This Earnings Season?
Dan Carroll, The Motley Fool - Motley Fool - Wed Apr 23, 5:30PM CDT
Earnings season already has produced its fair share of surprises, but big pharma's hardly even broken out of the gate so far. However, a trio of major drugmakers are set to release their quarterly results in the next two weeks, and all eyes in the...
Bristol-Myers, Samsung BioLogics Extend Ties - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 4:30PM CDT
Bristol-Myers Squibb Company (BMY) expanded its existing manufacturing agreement with Samsung BioLogics.
AbbVie Files for HCV Combination Therapy in U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 4:21PM CDT
AbbVie submitted a NDA to the FDA for its investigational hepatitis C virus infection therapy.
Say Hello to the New Fastest Growing Drug in History!
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 23, 9:03AM CDT
Take every guess you had as to how well Gilead Sciences would perform in the first-quarter, no matter how outrageous, and completely throw them out the window because Gilead would have trumped it! Break out your thesaurus because you'll need...
Global T-Cell Leukemia Therapeutics Pipeline Review 2014 - Analysis of 10 Companies & 14 Drug Profiles
M2 - Wed Apr 23, 8:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/943p82/tcell_leukemia) has announced the addition of the "T-Cell Leukemia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of T-Cell Leukemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for T-Cell Leukemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the T-Cell Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the T-Cell Leukemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Kyowa Hakko Kirin Co., Ltd. - Nippon Kayaku Co., Ltd. - Pfizer Inc. - Celgene Corporation - Mundipharma International Limited - Pharmacyclics, Inc. - Stemline Therapeutics, Inc. - CytImmune Sciences, Inc. - Applied Immune Technologies Ltd Drug Profiles - mogamulizumab - forodesine hydrochloride - lenalidomide - Anti-Tac(Fv)-PE38 Immunotoxin - PF-03084014 - BMS-906024 - PCI-34051 - SL-101 - Lenaldekar - CYT-91000 - NK-314 - Immunotoxins - TCRL Antibodies For HTLV-1 - L1AD3 For more information visit http://www.researchandmarkets.com/research/94...l_leukemia